中国组织工程研究与临床康复第13卷第44期2009–10–29出版JournalofClinicalRehabilitativeTissueEngineeringResearchOctober29,2009Vol.13,No.44ISSN1673-8225CN21-1539/RCODEN:ZLKHAH87831DepartmentofPharmaceutics,2ForeignAffairsOffice,FourthAffiliatedHospital,GuangxiMedicalUniversity,Liuzhou545005,GuangxiZhuangAutonomousRegion,ChinaWuMin,Pharmacist-in-charge,DepartmentofPharmaceutics,FourthAffiliatedHospital,GuangxiMedicalUniversity,Liuzhou545005,GuangxiZhuangAutonomousRegion,Chinapretty_bbu@yahoo.com.cnReceived:2008-12-22Accepted:2009-03-30(20081222023/D)WuM,LiangCF,WuHW,ZhouLF.Therapeuticdrugmonitoringofcyclosporin-AfollowingthefirsthearttransplantationinGuangxiZhuangAutonomousRegionofChina.ZhongguoZuzhiGongchengYanjiuyuLinchuangKangfu.2009;13(44):8783-8786.[http://www.crter.cnhttp://en.zglckf.com]Therapeuticdrugmonitoringofcyclosporin-AfollowingthefirsthearttransplantationinGuangxiZhuangAutonomousRegionofChinaWuMin1,LiangChen-fang1,WuHong-wen1,ZhouLi-fang2AbstractBACKGROUND:DuetothedifferenceinbioavailabilityandpharmacokineticsofcyclosporineA(CsA)amongdifferentindividu-als,itisofgreatimportancetocarryoutblooddrugconcentrationmonitoringforsafety,effectivenessandreductionofacuteimmunologicalrejection.OBJECTIVE:TodevelopamethodofblooddrugconcentrationdeterminationofCsAafterthehearttransplantation,andtoana-lyzethecorrelationbetweendose,outcomeandconcentrationsoastodevelopanoptimaladministrationscheme.DESIGN,TIMEANDSETTING:ControlledsampleobservationwasconductedbetweenAugustandSeptember2003attheClinicalPharmaceuticLaboratory,FourthAffiliatedHospital,GuangxiMedicalUniversity.PARTICIPANT:HearttransplantationpatientintheGuangxiZhuangAutonomousRegionwastreatedwithCsAcapsule,predni-soneandmycophenolatemofetil.METHODS:3mLvenousbloodwastakenfromthereceptorbeforetakingmedicineinthemorning.Asananticoagulant,heparinwasaddedandmiscedbene.10µLCsB,theininternalstandardfluidwasinsertedintoa10mLglasstube,whichwasaddedwith1mLwholebloodand1mLNaOH(0.2mol/L)andmiscedbene.Thesupernatantwasputintoanothertubeanddriedoutat60℃,againcooledtoroomtemperatureandaddedwith100µLsolutionof0.05mol/Lacidhydrocandacetonitrileplus400µLN-hexane,whichwascentrifugedfor5minutes,and20µLfromlowerlayerwastakenforsampleinjection.Ahighefficiencyliquidchromatographywasusedwithcyclosporine-Bastheinternalstandard,thepatientbloodconcentrationofCsAwasdetectedat214nmandthedosewasadjustedaccordingly.MAINOUTCOMEMEASURES:Whetherpatientsoccurredacuterejectionornot,andblooddrugconcentrationofCsAweremeasured.RESULTS:Highefficiencyliquidchromatographyshowedgoodresolvingpower.Theabsoluterecoverieswerenotlowerthan75%.Monitoringresultsdemonstratedthatthehighestconcentrationoccurred10daysaftertransplantation.Thedosewasregu-latedaccordingtoresults.Peakconcentrationwasbetween200-300µg/L14daysfollowingtransplantation,andacuterejectiondidnotoccurinrecipients.CONCLUSION:HighefficiencyliquidchromatographycansatisfythedemandofgeneralclinicdeterminationofbloodconcentrationofCsA.Peakconcentrationbetween200-300µg/L14daysfollowingtransplantationissuitable.INTRODUCTIONHearttransplantationistheimportanttherapyforfinalstageheartdiseases,whichcannotbecuredbyinternalmedicalorsurgicaltreatment.Aproperimmunosuppressivetherapyisoneofthekeyfac-torsforalong-termsurvivalafterhearttransplanta-tion[1].Cyclosporine-A(CsA)isthemosteffectiveimmunodepressantatpresent,andiswidelyusedinorgantransplantation,suchasliver,kidneyandbonemarrow.Itcansignificantlysuppressimmu-nologicalrejectionandimprovethesurvivalratesofthetransplantedorgans[2].DuetothedifferenceinbioavailabilityandpharmacokineticsofCsAamongdifferentindividuals,itisofgreatimportancetocarryoutblooddrugconcentrationmonitoringforsafety,effectivenessandreductionofimmunologi-calrejection.Thispaperreferredtorelevantre-ports[3-5]andexperimentalresearch,highefficiencyliquidchromatographywasusedwithCyc-losporine-Bastheinternalstandard,whichissimple,fastandaccuratetodetermineblooddrugconcen-trationofCsA.Thefirstcasewithhearttransplanta-tioninGuangxiZhuangAutonomousRegionofChinain2003wasmonitoredattheFourthAffiliatedHospital,GuangxiMedicalUniversityinthiswayandtheoutcomewassatisfactory.SUBJECTANDMETHODSDesignControlledsamplestudy.TimeandsettingExperimentswereconductedbetweenAugustandSeptember2003attheClinicalPharmaceuticLabo-ratory,FourthAffiliatedHospital,GuangxiMedicalUniversity.SubjectThefemalepatientaged54yearsold,receivedhearttransplantationonAugust29,2003.Immunosuppres-santsincludedCsAcapsule,prednisoneandmyco-phenolatemofetil(MMF),amongwhich,doseoforalCsAcapsulewas200-300mg/dandthelowestcon-centrationwas85.7µg/Lwithhighestconcentrationof618.0µg/Landmeanconcentrationof278.3µg/L.Informedconsentwasobtainedfromthesubject,whichisinaccordancewithAdministrativeRegula-tionsonMedicalInstitution,formulatedbyStateCouncilofthePeople’sRepublicofChina[6].ClinicalMedicineWuM,etal.Therapeuticdrugmonitoringofcyclosporin-Afollowingthefirsthearttransplantationin…8784P.O.Box1200,Shenyang110004cn.zglckf.comwww.CRTER.orgMainmedicine,reagentandinstrumentSourceCsAcontrolandCsBcontrolFujianMicrobiogyResearchInstitute,ChinaCausticsoda,aetherandacidumhydrochloricumareanalyticalpureXinningChemicalPlant,Shan-tou,GuangdongProvince,ChinaAcetonitrilechromatographicpureShanghaiChemicalAgentCo.,ChinaLC-10AtvphighefficiencyliquidchromatographySHIMADZUCORPORATION,JapanSPD-10AtvpdetectorShanghaiFirstMedicalCollegeEquipmentFactory,ChinaXW-80vortexadmixerShanghaiFirstMedicalCollegeEquipmentFactory,China80-2centrifugationmachineShanghaiSurgicalInstrumentFactory,ChinaMethodsChromatographicconditions:SHIMADZU-C18(10µm,250mm×4.6mm)analyticalcolumn;Columntemperatureis68℃;Wavelengthis214nm;acetonitrile-methanol-water(6:2:2，V/V);Flowspeedis1.4mL/min,volumeofsampleinjectionquantizationtubeis20µL.Bloodsamplemanagement:3mLvenousbloodwastakenfromthereceptorbeforetakingmedicineinthemorning.Asananticoagulant,heparinwasaddedandmiscedbene.10µLCsB,theininternalstandardfluidwasinsertedintoa10mLglasstube,whichwasaddedwith1mLwholebloodand1mLNaOH(0.2mol/L)andmiscedbene,keptitstillfor5minutesandthenaddedwith5mLaether,swungfor1minuteandcentrifugedfor10minutes(3000r/min).Thesupernantwasputintoanothertubeanddriedoutat60℃,againcooledtoroomtemperatureandaddedwith100µLsolutionof0.05mol/Lacidhydrocandacetonitrile(4:6)plus400µLN-hexane,whichwascentrifugedfor5minutesand20µLfromlowerlayerwastakenforsampleinjection[7-8].Standardcurve:Withconcentrationsof52,104,208,312,416,520,1040µg/L,CsAstandardproductswereaddedintoblankhumanwholebloodsamples,andthenaddedwith20µLinter-nalstandardfluidsrespectively,whichweredealtwiththeabovemanagementmethods.LinearregressionofCsAconcentrationswasdonebyusingCsA/CsBpeakarearatio.Equationsofy=0.002327x–0.019wereobtained,withcoefficientcorrelationofr=0.9995.Thelowestdetectableconcentrationwas20µg/Lwiththismethod.Authenticationofthemethods:Fortheprecisionofcalculation,relativestandarddeviation(RSD)oftheinter-dayassay(n=5)andintra-dayassay(n=5)werelowerthan10%amongthethreedifferentconcentrations(low,middleandhigh).MainoutcomemeasuresWhetherpatientsoccurredacuterejectionornot,andblooddrugconcentrationofCsAweremeasured.Design,enforcementandevaluationThefirstauthorcompletedexperimentdesign.Thefirstandthethirdauthorswereresponsibleforimplementation,andthesecondauthorwasresponsibleforevaluation.Alltheauthorsreceivedprofessionaltraining.StatisticalanalysisThedatawereanalyzedbythefirstauthorwithstatisticsoft-wareSPSS10.0.Itshowedlinearregressionofcorrelationbetweenthetwovariancewithsampledatacalculationofcoef-ficientofdifferentiationbyRSD.RESULTSChromatogramUnderthischromatographiccondition,chromatogramofthesampleandinternalstandardwasshowninFigure1.ThepreservationdurationsforCsBandCsAwere14.4minutesand18.08minutes,respectively,withstrongresolvingpowerandgooddisassociationfromthehetero-peaksoftheblood.AbsoluterecoveriesSampleswithCsAconcentrationsof104,416and1040µg/Lwerepreparedwithblankwholeblood,dealtwiththeabovemethods.TheactualvaluesobtainedandthecontrolproductswithequalconcentrationofCsAweredeterminedandcom-pared(n=5).Theabsoluterecoverieswerenotlowerthan75%(Table1).Figure1Highefficiencyliquidchromatography(HPLC)chromatogramsofCyclosporine-A(CsA)andCyclosporine-B(CsB)a:Blankhumanwholebloodb:HumanwholebloodwithCsAandCsBc:BlankhumanwholebloodwithstandardCsAandCsBTable1TheabsoluterecoveriesofCyclosporine-A(CsA)andrelativestandarddeviation(RSD)inhumanwholeblood(x_±s,n=5)Concentration(µg/L)Recoveryrate(%)RSD(%)10479.4±5.67.0541684.2±4.45.22104087.3±2.93.32WuM,etal.Therapeuticdrugmonitoringofcyclosporin-Afollowingthefirsthearttransplantationin…ISSN1673-8225CN21-1539/RCODEN:ZLKHAH8785www.CRTER.orgSampleswithCsAconcentrationsof104,416and1040µg/Lwerepreparedwithblankwholeblood,dealtwiththeabovemethods.Theresultswerecalculatedwithstandardcurveequationstoobtainrelativerecoveries(Table2).MedicineconcentrationThelowestconcentrationwasduetopoorconditionsaftersur-geryandthemedicinescouldnotbeabsorbedwell;thehighestconcentrationoccurred10daysaftersurgeryduetothepatientbeinggivenmedicinesmorefrequently.AdministrationdoseandconcentrationofCsAwithin2weeksfollowingtransplantationwereasfollows.DateUseofimmunosuppressantCyclosporine-A(CsA)minimumconcentration(µg/L)08-30CsA100mg,Bid;prednisone25mg,Bid;mycophenolatemofetil(MMF)0.5g,Tid134.908-31Asabove85.709-01CsA150mg,Bid;prednisone25mg,Bid;MMF0.5g,Tid237.609-02CsA100mg,Bid;prednisone20mg,Bid;MMF0.5g,Tid472.709-03Asabove411.909-04CsA100mg,Bid;prednisone15mg,Bid;MMF0.5g,Tid133.109-05Asabove208.709-06CsA150mg,Bid;prednisone15mg,Bid;MMF0.5g,Tid116.009-07Asabove355.909-08CsA100mg(morning),150mg(eve-ning);prednisone15mg,Bid;MMF0.5g,Tid618.009-09Asabove562.809-10Asabove177.009-11Asabove292.409-12Asabove240.809-13CsA125mg,Bid;prednisone15mg,Bid;MMF0.5g,Tid204.409-14Asabove200.9DISCUSSIONThebestflow,acetonitrile-methanol-water(6:2:2)todisassoci-ateCsAandCsBwithhighefficiencyliquidchromatography[9-11].Thehigherofcolumntemperature,thebetterofpeakshapewas.Inordertoprotectthechromatobarandensurestabilityofthebaseline,wemadethecolumntemperatureat68℃.Inthestudyofthealkalinizedbloodsample,itwasfoundthatthehigherconcentrationoftheNaOH(0.1-1.0mol/L),thehighertheabsoluterecoveries,butwithmanyhetero-peaksinterferingwiththemainpeak.Itshowedthat0.2mol/Lwasthebest[12-15].Thismethodrequiredsingleextractionandthereagentswereeasytoobtain.ThecycleofdeterminationwasshortwithCsBasinternalstandard,whichisrarelyreported.Itismucheasier,fasterandmoreaccurateandreliablecomparedtotheothermethods,whichcaneffectivelyguideclinicalapplicationofCsAandimprovemedicalquality.Atpresent,immunosuppressantsareoftenusedagainstheartrejection.Inthishospital,thefirstcasewithhearttransplantationreceivedCsA,prednisoneandMMFbefore,duringandaftersurgerytomakeasuccessfulsurgeryandimprovethepatient’slifequality[16-18].Meanwhile,dailywholeblooddrugconcentrationwasmonitoredandthedosewasadjustedaccordinglyandthedrugconcentrationwaskeptbetween200-300µg/Latday14aftersurgery.Noacuterejectionoccurredonthereceptor.Combiningrelevantstatistics,weholdthatwholeblooddrugconcentrationofCsAshouldbekeptat200-300µg/Lwithinthreemonthsaftersurgery.REFERENCES[1]LiJT.LinchuangYailixue.Beijing:ThePublishingHouseofPeople’sHealth.1998:1327[2]ChenXD,JinYY.XinbianYaowuxue.Beijing:ThePublishingHouseofPeople’sHealth.2007:765[3]ChenJS,DuQY,HuangHL,etal.DeterminationofCyclosporinAConcentrationinHumanWholeBloodbySingle-stepExtractionRP-HPLCMethod.JiefangjunYaoxueXuebao.2004;20(03):357-359.[4]RenB,LiSX,ChenX,etal.DeterminationofcyclosporineAinhumanwholebloodbyRP-HPLC.ZhongguoYiyuanYaoxueZazhi.2001;21(8):407.[5]WangQB,TuZL,WangF,etal.DeterminationofcyclosporineAinthewholebloodoforgantransplantationpatientsbyHPLC/electrosprayionization-MS(HPLC/ESI+-MS).ZhongguoYiyuanYaoxueZazhi.2003;23(4):217.[6]StateCouncilofthePeople'sRepublicofChina.AdministrativeRegulationsonMedicalInstitution.1994-09-01.[7]NamHS,McAnultyJF,KwakHH,etal.Gingivalovergrowthindogsassociatedwithclinicallyrelevantcyclosporinebloodlevels:observationsinacaninerenaltransplantationmodel.VetSurg.2008;37(3):247-253.[8]IzumiN,FurukawaT,SatoN,etal.Riskfactorsforacutegraft-versus-hostdiseaseafterallogeneichematopoieticstemcelltransplantation:retrospectiveanalysisof73patientswhoreceivedcyclosporinA.BoneMarrowTransplant.2007;40(9):875-880.[9]SegerC,TentschertK,StögglW,etal.ArapidHPLC-MS/MSmethodforthesimultaneousquantificationofcyclosporineA,tacrolimus,sirolimusandeverolimusinhumanbloodsamples.NatProtoc.2009;4(4):526-534.[10]SahinG,AkayOM,KusE,etal.EffectsofimmunosuppressivedrugsonplateletaggregationandsolubleP-selectinlevelsinrenaltransplantpatients.RenFail.2009;31(2):111-117.[11]WangSM,LaiMK,ChuehSC,etal.OptimalC2concentrationofcyclosporincorrectedwithgoodefficacyandsafetyinAsiankidneytransplantrecipients.TransplantProc.2008;40(7):2243-2244.[12]VenturaE,BonardetA,PageauxGP,etal.CalcineurinInhibitorDeterminationinWholeBloodWiththeRXLDimensionAnalyzer:AUsefulToolforImmunosuppressiveDrugMonitoring.TransplantProc.2009;41(2):707-709.[13]BrunsteinCG,CanteroS,CaoQ,etal.Promisingprogression-freesurvivalforpatientslowandintermediategradelymphoidmalignanciesafternonmyeloablativeumbilicalcordbloodtransplantation.BiolBloodMarrowTransplant.2009;15(2):214-222.[14]HuangXS,YangGF,PanYC.EffectofberberinhydrochlorideonbloodconcentrationofcyclosporineAincardiactransplantedrecipients.ZhongguoZhongXiyiJieheZazhi.2008;28(8):702-704.[15]BöhlerT,NoltingJ,KamarN,etal.Validationofimmunologicalbiomarkersforthepharmacodynamicmonitoringofimmunosuppressivedrugsinhumans.TherDrugMonit.2007;29(1):77-86.[16]BartenMJ,RahmelA,BoldtA,etal.Pharmacodynamicmonitoringoftheimmunosuppressivetherapyinpatientsafterhearttransplantation:wholebloodflowcytometricanalysisoflymphocytefunction.ComputBiolMed.2007;37(10):1367-1373.Table2TherelativerecoveriesofCyclosporine-A(CsA)andrelativestandarddeviation(RSD)inhumanwholeblood(n=5)Concentration(µg/L)Recoveryrate(%)RSD(%)10494.7±3.94.12416103.6±5.75.50104099.2±2.82.82WuM,etal.Therapeuticdrugmonitoringofcyclosporin-Afollowingthefirsthearttransplantationin…8786P.O.Box1200,Shenyang110004cn.zglckf.comwww.CRTER.org[17]WadaK,TakadaM,UedaT,etal.PharmacokineticstudyandlimitedsamplingstrategyofcyclosporineinJapanesehearttransplantrecipients.CircJ.2006;70(10):1307-1311.[18]HodaMR,GrimmM,LauferG.Predictionofcyclosporinebloodlevelsinhearttransplantationpatientsusingapharmacokineticmodelidentifiedbyevolutionaryalgorithms.JHeartLungTransplant.2005;24(11):1855-1862.广西首例心脏移植患者术后环孢素A的药物监测吴敏1，梁陈方1，吴洪文1，周丽芳2(广西医科大学第四附属医院，1临床药学科，2涉外办，广西壮族自治区柳州市545005)吴敏，女，1976年生，广西壮族自治区桂平市人，汉族，于1999年毕业于桂林医学院药学系，理学学士，主管药师，主要从事临床药学和药事管理的工作。摘要背景：口服环孢素A的生物利用度和药代动力学个体差异大，故进行药物血药浓度监测，对安全、有效地用药和减少急性排斥反应具有重要临床意义。目的：建立心脏移植后环孢素A血药浓度监测方法，分析药物浓度与剂量、疗效的关系，建立最佳给药方案。设计、时间及地点：样本对照观察，2003-08/09在广西医科大学第四附属医院药剂科临床药学实验室完成。对象：广西壮族自治区首例心脏移植患者，环孢素A胶囊、强的松、霉酚酸酯三联用药治疗。方法：受者早上服药前取静脉血3mL，肝素抗凝，混匀。在10mL具塞玻璃试管内加入内标环孢素B贮备液10µL，加入1mL全血，再加入0.2mol/LNaOH溶液1mL，混匀。取上清液加入另一试管，于60℃水浴挥干，冷却至室温，残渣加入0.05mol/L盐酸与乙腈混合液100µL溶解，再加入400µL正己烷洗涤，离心5min，取下层液20µL进样。运用高效液相色谱法以环孢素B为内标、214nm处紫外检测，对心脏移植受者进行环孢素A血药浓度监测，并及时给予用药剂量调整。主要观察指标：患者是否出现急性排斥反应，环孢素A血药谷浓度。结果：受者高效液相色谱法分析有很好的分离度，环孢素A绝对回收率均不低于75%。监测结果显示环孢素A药物最高浓度产生在移植后第10天，根据结果及时调整用药剂量，移植后14d谷浓度维持在200~300µg/L，受者未出现急性排斥反应。结论：高效液相色谱法能满足心脏移植后环孢素A的血药浓度监测需求，心脏移植后短期环孢素A血药谷浓度维持在200~300µg/L较适合。关键词：心脏移植；环孢素A；药物浓度监测；高效液相色谱法doi:10.3969/j.issn.1673-8225.2009.44.043中图分类号:R617文献标识码:B文章编号:1673-8225(2009)44-08783-04吴敏，梁陈方，吴洪文，周丽芳.广西首例心脏移植患者术后环孢素A的药物监测[J].中国组织工程研究与临床康复，2009，13(44):8783-8786.[http://www.crter.orghttp://cn.zglckf.com](EditedbyQiuY/WangL)根据国际医学期刊编辑委员会、美国医学会及西方生物医学期刊的政策，本刊对发表英文体例文章作如下说明：1.本刊建议优秀原创性论著以英文体例在本刊优先发表，以利于国际传播。2.在专业学术会议上做过口头报告或者以摘要或会议墙报的形式发表过初步研究结果的完整报告，可在本刊以英文体例发表。3.以中文形式首次发表后的文章，其内容充实了50%数据的学术论文，可在中文出版后7天以英文体例在本刊发表。4.根据“对于不同文种的同一论文在1种期刊的2种或多种版本上同时或相继发表，国内外均无较大争议”的国际规范，《中国组织工程研究与临床康复》杂志在目前已争取但尚未获批准英文版本的情况下，可对本刊已发表的优秀稿件在征求作者同意的情况下，以英文体例在本刊再次发表。但此类文章数量应较少，每期出版不能大于1篇。此类文章的发表不属于作者一稿两投，也非作者违反版权法和不道德的行为。5.借鉴中华医学会杂志社关于“高质量、有影响的论文在国外发表后，应该鼓励在国内以中文形式介绍有关的研究”,“中华医学会杂志社经过认真考虑，决定在中华医学会系列杂志中开设‘在国外发表的优秀中国论文介绍’栏目，其目的是有利于加强国内的学术交流，让国内更多读者共享我国的科研成果”的举措。本刊亦开设“在国外发表的优秀中国论文介绍”之栏目，在国外发表的优秀英文稿件可以用中文形式在本刊发表，并欢迎作者投稿。这样的稿件出版，不属于作者一稿两投及违反版权法和不道德的行为。《中国组织工程研究与临床康复》杂志关于组织发表英文稿件的相关说明ISSN1673-8225CN21-1539/R2009年版权归《中国组织工程研究与临床康复》杂志社所有
